7:39 AM ET
8-K
Clinical Trial Data
Monte Rosa Therapeutics Clinical Trial Data
Monte Rosa Therapeutics announced positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader for inflammatory diseases. The GFORCE-1 study in 108 subjects showed 80-90% NEK7 degradation and normalization of key ASCVD pathogenic drivers with a favorable safety profile, supporting the planned initiation of multiple Phase 2 studies in coronary artery disease, gout, and hidradenitis suppurativa.
- Earnings call
- Oct 1, 2026, 8:00 AM ET